OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-κB pathway and stress response signaling

Carcinogenesis

Volumn 30, Issue 10, 2009, Pages 1702-1709

  Weng, Jing Ru ^b   Tsai, Chen Hsun ^a   Omar, Hany A ^a   Sargeant, Aaron M ^a   Wang, Dasheng ^a   Kulp, Samuel K ^a   Shapiro, Charles L ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; [1 (4 CHLORO 3 NITROBENZENESULFONYL) 1H INDOL 3 YL]METHANOL; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSU A 9; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG TARGETING; DRUG TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENES, REPORTER; HUMANS; INDOLES; LUCIFERASES; METHANOL; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 70349986398     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp202     Document Type: Article

References (50)

1. Frantz,S. (2005) Drug discovery: Playing dirty. Nature, 437, 942-943.
2. Reed,G.A. et al. (2005) A phase I study of indole-3-carbinol in women: Tolerability and effects. Cancer Epidemiol. Biomarkers Prev. 14, 1953-1960.
3. Reed,G.A. et al. (2006) Single-dose and multiple-dose administration of indole-3-carbinol to women: Pharmacokinetics based on 3,3′-diindolylmethane. Cancer Epidemiol. Biomarkers Prev., 15 2477-2481.
4. Aggarwal,B.B. et al. (2005) Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 4, 1201-1215.
5. Kim,Y.S. et al. (2005) Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem., 16, 65-73.
6. Manson,M.M. (2005) Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol. Eur. J. Cancer, 41, 1842-1853.
7. Rogan,E.G. (2006) The natural chemopreventive compound indole-3-carbinol: State of the science. In Vivo, 20, 221-228.
8. Weng,J.R. et al. (2008) Indole-3-carbinol as a chemopreventive and anticancer agent. Cancer Lett., 262, 153-163.
9. Auborn,K.J. et al. (2003) Indole-3-carbinol is a negative regulator of estrogen. J. Nutr., 133, 2470S-2475S.
10. Wang,T.T. et al. (2006) Estrogen receptor alpha as a target for indole-3-carbinol. J. Nutr. Biochem., 17, 659-664.
11. Parkin,D.R. et al. (2004) Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect. Prev., 28, 72-79.
12. Chao,W.R. et al. (2007) Computer-aided rational drug design: A novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling. J. Med. Chem. 50, 3412-3415.
13. Kassouf,W. et al. (2006) Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl) -1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res., 66, 412-418.
14. Cho,S.D. et al. (2007) Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Res., 67, 674-683.
15. Brandi,G. et al. (2003) A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res., 63, 4028-4036.
16. Weng,J.R. et al. (2007) A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res., 67, 7815-7824.
17. Chinni,S.R. et al. (2002) Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin. Cancer Res. 8, 1228-1236.
18. Rahman,K.M. et al. (2004) Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr. Cancer, 48, 84-94.
19. Mitsuuchi,Y. et al. (2000) The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 60, 5390-5394.
20. Sa,G. et al. (2004) P27 expression is regulated by separate signaling pathways, downstream of Ras, in each cell cycle phase. Exp. Cell Res., 300, 427-439.
21. Helbig,G. et al. (2003) NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem., 278, 21631-21638.
22. Kukreja,P. et al. (2005) Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res., 65, 9891-9898.
23. Rahman,K.M. et al. (2006) Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol. Cancer Ther., 5, 2747-2756.
24. Li,Y.M. et al. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6, 459-469.
25. Liang,Z. et al. (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res., 65, 967-971.
26. Ueda,Y. et al. (2006) Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res., 66, 5665-5675.
27. Slamon,D.J. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
28. Zarubin,T. et al. (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res., 15, 11-18.
29. Liu,J. et al. (2005) Role of JNK activation in apoptosis: A double-edged sword. Cell Res., 15, 36-42.
30. Oyadomari,S. et al. (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ., 11, 381-389.
31. McCullough,K.D. et al. (2001) Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol., 21, 1249-1259.
32. Fan,S. et al. (2006) BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer, 94, 407-426.
33. Struewing,J.P. et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336, 1401-1408.
34. Thompson,D. et al. (2002) Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst., 94, 1358-1365.
35. Deng,C.X. (2006) BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res., 34 1416-1426.
36. Wang,C. et al. (2005) Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res., 65, 6557-6567.
37. Kohle,C. et al. (2007) Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem. Pharmacol., 73, 1853-1862.
38. Miao,W. et al. (2005) Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: Direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem., 280, 20340-20348.
39. Kohle,C. et al. (2006) Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem. Pharmacol., 72, 795-805.
40. Tamir,S. et al. (2002) The effect of oxidative stress on ERalpha and ERbeta expression. J. Steroid Biochem. Mol. Biol., 81, 327-332.
41. Hayashi,S.I. et al. (2003) The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer, 10, 193-202.
42. Grasso,P. et al. (1991) Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu. Rev. Pharmacol. Toxicol., 31, 253-287.
43. Sargeant,A.M. et al. (2007) Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol. Pathol., 35, 549-561.
44. Karin,M. (2006) NF-kappaB and cancer: Mechanisms and targets. Mol. Carcinog., 45, 355-361.
45. Zhou,Y. et al. (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer, 12 (suppl. 1): S37-S46.
46. Lazennec,G. et al. (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology, 142, 4120-4130.
47. Sotoca,A.M. et al. (2008) Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol. Sci., 105, 303-311.
48. Shaaban,A.M. et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol., 27, 1502-1512.
49. Yoshida,M. et al. (2004) Dietary indole-3-carbinol promotes endometrial adenocarcinoma development in rats initiated with N-ethyl-N'-nitro-N-nitrosoguanidine, with induction of cytochrome P450s in the liver and consequent modulation of estrogen metabolism. Carcinogenesis, 25, 2257-2264.
50. Crowell,J.A. et al. (2006) Indole-3-carbinol, but not its major digestive product 3,3′-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450. Toxicol. Appl. Pharmacol., 211, 115-123.